Spruce Biosciences (SPRB) Operating Leases (2020 - 2026)
Spruce Biosciences (SPRB) posted quarterly Operating Leases of $332000.0 for Q1 2026, down 49.62% year-over-year from $659000.0 in Q1 2025, and down 20.76% quarter-over-quarter from $419000.0 in Q4 2025.
Spruce Biosciences (SPRB) Operating Leases (2020 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Operating Leases for 7 consecutive years, with $332000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 49.62% year-over-year to $332000.0; the TTM figure through Mar 2026 stood at $332000.0 (down 49.62% YoY), while the FY2025 annual figure was $419000.0, down 43.07% from the prior year.
- Operating Leases fell to $332000.0 in Q1 2026 per SPRB's latest filing, from $419000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.4 million in Q3 2022 and bottomed at $332000.0 in Q1 2026.
- Historically, Operating Leases has averaged $898705.9 across 5 years, with a median of $950000.0 in 2024.
- Annual changes were most pronounced in 2023 — Operating Leases rose 4.46% — and 2026, when it plunged 49.62%.
- Spruce Biosciences' Operating Leases stood at $1.3 million in 2022, then retreated by 19.19% to $1.0 million in 2023, then fell by 27.77% to $736000.0 in 2024, then plunged by 43.07% to $419000.0 in 2025, then fell by 20.76% to $332000.0 in 2026.
- Business Quant data shows SPRB's Operating Leases at $332000.0 in Q1 2026, $419000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Spruce Biosciences | 122.59 Mn | 122.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 245,000.00 |
| Mar 31, 2026 | 332,000.00 |
| Dec 31, 2025 | 419,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | 659,000.00 |
| Dec 31, 2024 | 736,000.00 |
| Sep 30, 2024 | 809,000.00 |
| Jun 30, 2024 | 880,000.00 |
| Mar 31, 2024 | 950,000.00 |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.15 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 1.40 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 1.39 Mn |